GLP-1s Didn't Just Change Primary Care — They're Quietly Gutting Bariatric, Sleep, and Diabetes Device Practices That Have No Contingency Plan

The bariatric surgery department at Norman Regional Hospital in Oklahoma didn't close because of poor outcomes or physician retirement. It closed in the summer of 2024 because the patient volume dried up. The hospital cited anti-obesity medication adoption directly. This was the first documented closure of its kind, but it almost certainly won't be the last.

Across three specialty categories — bariatric surgery, sleep medicine, and diabetes device-dependent practices — the GLP-1 disruption has moved from hypothesis to balance sheet reality. The primary care story (protocols, prescribing volumes, formulary fights) gets most of the coverage. The more consequential story is what's happening downstream: procedure volumes cratering, device revenue plateauing, and specialists whose entire revenue architecture was built on managing conditions that GLP-1s now treat upstream.

With CMS's BALANCE model bringing Medicare GLP-1 access down to $50/month starting July 2026, the rate of change is about to compress further. The practices without a contingency plan are running out of time to build one.

The Volume Signal Specialists Are Ignoring: What the Procedure and Device Data Actually Shows

The clearest signal comes from bariatric surgery, where the numbers are stark enough to force a reckoning. A landmark study of 17 million privately insured Americans published in JAMA Network Open in October 2024 found that as GLP-1 prescriptions more than doubled between 2022 and 2023 (a 105.7% increase), bariatric surgery rates fell 8.7%. In August 2024 alone, bariatric procedures were down more than 32% compared to August 2022 across 809 hospitals.

The financial deterioration is even more telling than the volume data. Average total cost margin per bariatric procedure swung from a positive $1,651 in January 2021 to negative $504 by June 2024 — a $2,156 per-procedure collapse. A health system in the Philadelphia region canceled its planned bariatric expansion entirely. Vizient projects inpatient bariatric surgery will decline 15% by 2034.

For sleep medicine and diabetes devices, the picture is more complex but the directional pressure is identical: the conditions these specialties treat are being intercepted before patients reach the specialist.

Bariatric Surgery's Existential Reckoning — When the Disease You Treat Gets a Drug That Works

The clinical counterargument to GLP-1 displacement in bariatric surgery is legitimate. A 2025 head-to-head study from NYU Langone and NYC Health + Hospitals covering 51,085 patients found that bariatric surgery produced an average 58-pound loss (24% total body weight) over two years against GLP-1 therapy's 12-pound loss (4.7%). Surgery reduced cardiovascular risk by 40% versus 20% for GLP-1s. An Israeli cohort study found 62% lower mortality with surgical intervention.

The problem for bariatric practices isn't clinical inferiority — they're winning that argument. The problem is that patients and referring physicians are choosing the easier path first. And approximately 70% of GLP-1 patients discontinue within one year, meaning a large pool of treatment-naive, medically complicated patients will eventually cycle back to surgical candidacy. The practices that have maintained infrastructure and relationships will capture that volume. The ones that restructured or closed will not.

The bariatric programs demonstrating real resilience are those treating GLP-1 adoption as an operational redesign problem. Lehigh Valley Health Network deployed 18 da Vinci robotic systems across 8 locations and cross-trained bariatric surgeons in medical weight management — one campaign generated $3.12 million in variable contribution margin and a 30% increase in foregut procedures. The model reframes the bariatric program as the obesity medicine hub, with GLP-1 prescribing, surgical candidacy evaluation, and post-surgical pharmacotherapy all under one clinical infrastructure.

Surgeons who are still treating GLP-1s as competition rather than a pre-surgical optimization tool are misreading the market entirely.

Sleep Medicine's CPAP Cliff: How GLP-1-Driven OSA Remission Is Reshaping the Lab Revenue Model

The FDA's December 2024 approval of tirzepatide for obstructive sleep apnea created something sleep medicine has never faced: a pharmaceutical alternative to PAP therapy. The SURMOUNT-OSA trial published in NEJM showed tirzepatide reducing apnea-hypopnea index by 50.7% in patients not on PAP therapy at baseline, with 61.2% achieving greater than 50% AHI reduction — statistically extraordinary results for a disease that has been managed almost entirely through devices since the CPAP's introduction in 1981.

The near-term reality, however, inverts the obvious narrative. ResMed's own real-world data tracking over one million patients found that patients on GLP-1 medications are 11% more likely to initiate PAP therapy, with 6.2% higher re-supply rates at three years. The mechanism: GLP-1 prescribers are simultaneously diagnosing OSA that was previously undetected, funneling patients into sleep labs and CPAP prescriptions. ResMed posted 10-15% revenue growth through 2025-2026, with U.S. mask and accessories sales growing 16%.

Sleep medicine practices that rely heavily on PAP-dependent revenue should not read ResMed's numbers as vindication. ResMed benefits from the diagnosis wave regardless of whether patients ultimately transition to pharmacotherapy. Sleep labs and sleep physicians face a structural shift: the disease is being recognized earlier (good for diagnosis volume), but first-line treatment is increasingly pharmaceutical (bad for device-dependent revenue). The practices without GLP-1 prescribing capacity or obesity medicine integration will find themselves in the referral chain but outside the treatment relationship.

Diabetes Device and Endocrinology Practices Are Watching Their Panel Migrate in Real Time

The diabetes device story is the most nuanced of the three. CGM adoption is accelerating, not declining, because GLP-1 patients benefit from continuous metabolic feedback — Abbott's FreeStyle Libre analysis found adherence rates higher in GLP-1 patients than in non-GLP-1 patients, and CGM usage among Type 2 non-insulin patients quadrupled between 2018 and 2022. Dexcom exceeded $1.1 billion in Q2 2025 revenue. The device market isn't collapsing — it's bifurcating.

The long-term structural risk concentrates in insulin pump dependency. As GLP-1s achieve glycemic control in Type 2 patients who previously required intensive insulin management, the pump market's Type 2 growth engine stalls. GlobalData Healthcare analysts warn that while near-term impacts appear manageable, "long-term impacts appear gloomy" for insulin pumps specifically, as fewer patients progress to the insulin dependency that drives pump candidacy.

For endocrinology and diabetes-focused practices, the panel disruption is more immediate and personal. GLP-1 prescribing has migrated aggressively into primary care and direct-to-consumer telehealth platforms. The American Diabetes Association's 2026 Standards of Care now position dual GIP/GLP-1 receptor agonists as preferred agents across multiple comorbidity profiles — protocols general practitioners are now expected to execute without specialist referral. The endocrinologist's traditional role as obesity and glycemic management specialist is being upstreamed away.

The CMS Voluntary Model Is the Tipping Point — Why Broader Medicare Access Accelerates the Specialty Crisis

Everything described above has unfolded with GLP-1s still largely inaccessible to Medicare beneficiaries and priced above $1,000/month at retail. The CMS BALANCE model, launching Medicare GLP-1 access at $50/month in July 2026 with a negotiated net price of $245 per 30-day supply, changes the denominator of the affected patient population fundamentally.

Eligibility criteria cover BMI ≥ 35, BMI ≥ 30 with heart failure or hypertension, and BMI ≥ 27 with cardiovascular history — population-level criteria that describe a substantial share of the Medicare patient base. OSA is explicitly included as a qualifying comorbidity. Novo Nordisk and Eli Lilly both committed to participate.

This isn't an incremental policy adjustment. Medicare's historically obese beneficiary population has been largely unable to afford GLP-1 therapy. Starting July 2026, many of them will access it for $50/month. The bariatric pipeline, the CPAP diagnosis-to-device funnel, and the diabetes specialist panel will all feel this simultaneously. Specialty practices that have spent the past two years telling themselves that access barriers would slow the GLP-1 wave no longer have that argument available.

The Pivot Menu: Which Specialty Repositioning Strategies Have Actual Evidence Behind Them

The practices with documented survival strategies share a common architecture: they stopped defining themselves by procedure or device category and started defining themselves by condition ownership. Obesity is a chronic, systemic disease. The practices that treat it as such — combining pharmaceutical management, surgical candidacy evaluation, device monitoring, and behavioral support under one clinical relationship — have pricing power and patient retention that procedure-only models cannot replicate.

The Lehigh Valley bariatric-to-obesity-medicine pivot is the most concrete example with published financials. The "cancer model" framing — treating obesity as a chronic disease requiring combined pharmaceutical and surgical intervention over time rather than a one-time procedure — gives bariatric programs clinical and economic rationale for maintaining GLP-1 prescribing capacity alongside OR volume.

For sleep medicine, the pivot involves leaning into the diagnosis wave rather than mourning the device revenue. Practices that build obesity medicine relationships will see their diagnostic volume grow as GLP-1 prescribers refer for OSA evaluation. The revenue model shifts from device-dependent to evaluation and management (E&M) intensive — less recurring supply revenue, more clinical complexity billing.

For diabetes and endocrinology practices, the sustainable position is managing GLP-1 failure and complexity, not competing with primary care on initial prescribing. The ~70% discontinuation rate within one year creates a large, medically complex referral population that primary care cannot manage independently. Endocrinologists who position as the specialist for multi-drug failure, combination surgical-pharmacological candidates, and cardiometabolic complexity will have panels. Those competing for first-line prescribing volume against telehealth platforms offering semaglutide at scale will lose.

The window for this repositioning is not infinite. Once the BALANCE model's Medicare access fully activates in January 2027, the treated population expands dramatically and the competitive pressure on specialist-as-procedure-provider intensifies further. The practices that restructure in the next 18 months will define the post-GLP-1 specialty landscape. The ones waiting for volume to stabilize are waiting for a stabilization that isn't coming.